The Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia.
Florey Department of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia.
Front Public Health. 2024 Jul 23;12:1425195. doi: 10.3389/fpubh.2024.1425195. eCollection 2024.
Pharmacological management is a vital aspect of dementia care. Suboptimal medication prescribing and adverse drug reactions are major causes for ongoing concerns for the quality of care. This review aims to investigate the existence and comprehensiveness of Australian guidelines dedicated to supporting dementia care in the context of pharmacological management.
Guideline registries and databases (EMBASE and CINAHL) were searched to identify Australian guidelines addressing pharmacological management in dementia care and to uncover barriers and considerations associated with guideline implementation.
Seven Australian guidelines were identified. Barriers to effective implementation were identified at individual, provider, and system levels. None of the identified guidelines provided comprehensive guidance on management of multimorbidity and polypharmacy.
Although Australian guidelines are available to guide pharmacological management in dementia, several barriers impede their effective implementation. There is an urgent need for updated guidelines that address the management of multimorbidity and polypharmacy in people living with dementia.
药物治疗管理是痴呆症护理的重要方面。药物处方不当和药物不良反应是持续关注护理质量的主要原因。本综述旨在调查澳大利亚是否存在专门针对痴呆症药物治疗管理方面的指南，以支持痴呆症护理。
检索指南登记处和数据库（EMBASE 和 CINAHL），以确定澳大利亚在痴呆症护理中针对药物治疗管理的指南，并发现与指南实施相关的障碍和考虑因素。
确定了 7 项澳大利亚指南。在个人、提供者和系统层面都发现了有效实施的障碍。确定的指南均未提供关于治疗共病和多药治疗的综合指导。
尽管澳大利亚有指南可用于指导痴呆症的药物治疗管理，但仍存在一些障碍阻碍其有效实施。迫切需要更新的指南来解决患有痴呆症的患者的共病和多药治疗管理问题。
